FDA
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Maison Solutions Inc. (NASDAQ: MSS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $22 at H.C. Wainwright
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Humana Inc. (NYSE: HUM); Jasper Therapeutics, Inc. (NASDAQ: JSPR); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Unicycive (UNCY) Will Seek Type A Meeting to Resolve CRL Issues: Benchmark
-
-
-
-
-
-
-
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

